Regarding childhood cancers, the use of CDK4/6 inhibitors has been applied only once on a small cohort of young patients affected by different types of tumors such as neuroblastoma, MRT, and rhabdomyosarcoma. This evidence concerns the gene CDK4 and neuroblastoma.